


believes could be resolved in a telephone interview, the Examiner is requested to telephone the Applicant's undersigned attorney.

Respectfully submitted,


Charles Berman
Reg. No. 29,249

OPPENHEIMER WOLFF & DONNELLY LLP
2029 Century Park East
38th Floor
Los Angeles, CA 90067-3024
Phone: (310) 788-5000
FAX: (310) 788-5100

ADDENDUM PAGES

VERSION MARKED TO REFLECT CHANGES

I. CHANGES IN THE TITLE

Please amend the title to read “ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS – OLIGONUCLEOTIDES FOR EXPRESSING XENOPUS FRAZZLED (FRZB-1) PROTEIN”.

II. CHANGES IN SPECIFICATION

1. The following shows the changes made to the paragraph originally found at page 1, line 14 of the specification:

[This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.] This application is a Divisional of Application Serial No. 09/552,988 filed April 21, 2000, which claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996.

III. CHANGES IN THE CLAIMS

9. (Amended) An oligonucleotide construct comprising a sequence coding for a protein and an expression vector operatively linked therewith, the protein being expressible from [SEQ ID NO:4,] SEQ ID NO:8 [or SEQ ID NO:10].

10. The construct as in claim 9 wherein the protein is expressible in soluble form.

11. The construct as in claim 9 wherein the expression vector is a mammalian or viral expression vector.